← Oyster Point Pharma, Inc. (OYST) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Oyster Point Pharma, Inc. (OYST)
Biotechnology · market cap —
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
None scheduled
Pipeline
7
programs
Upcoming events
0
next 90d+
Dossier
Not yet
generate it
The catalyst path
No upcoming catalysts in our calendar.
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| OC-01 Low Dose, 0.12 mg/mL | Phase 3 | Long Term Follow up Dry Eye Disease |
| OC-02 (simpinicline) nasal spray | Phase 2 | Dry Eye Disease |
| OC-01 (varenicline) nasal spray | Phase 3 | Dry Eye Disease (DED) |
| OC-01 (varenicline) nasal spray 1.2 mg/ml | Phase 2 | Neurotrophic Keratopathy |
| OC-01 0.1% 0.6 mg/ml | Phase 2 | Dry Eye Disease |
| 0.2 % hemigalactarate (0.11% free base) 0.2 % OC-02 Low Dose (1.1 mg/mL) | Phase 2 | Dry Eye Disease |
| Varenicline Tartrate Nasal Spray | Phase 3 | Dry Eye Disease |
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for OYST (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 7 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.